KO Client Modella AI Acquired by AstraZeneca

KO client Modella AI, a leader in artificial intelligence for life sciences, was recently acquired by AstraZeneca, expanding the companies’ existing collaboration to advance the application of multi-modal AI foundation models and AI agents across AstraZeneca’s global oncology portfolio.

The acquisition will integrate Modella AI’s generative and agentic AI platform into AstraZeneca’s oncology R&D environment. Building on the multi-year agreement announced in July 2025, the integration is expected to generate new biological and clinical insights while enabling greater automation, scalability, and consistency across data-intensive workflows—supporting efforts to accelerate clinical development, advance biomarker discovery, and drive the next wave of data-driven decision-making across the oncology pipeline.

“Modella AI was built at the intersection of pathology, clinical data, and advanced generative AI to tackle some of the hardest problems in oncology,” said Faisal Mahmood, PhD, co-founder of Modella AI and Professor at Mass General Brigham. “Integrating our foundation models directly into AstraZeneca’s research ecosystem will help translate methodological advances into real-world impact faster.”

“By joining AstraZeneca, we can apply our multimodal foundation models and agentic AI platform across a world-class oncology pipeline to accelerate development and help improve outcomes for patients with cancer,” added Jill Stefanelli, PhD, co-founder and Chief Executive Officer of Modella AI.

Partners Kevin Gibson and Brad Schoenfeld led the KO team which also included partner Chris Achatz, attorneys Elizabeth Ho and Nadia Bryan, and paralegal Sara Richissin. Learn more in the announcement and in Reuters.